Bora Pharmaceuticals
保瑞藥業股份有限公司

Bora Pharmaceuticals Reports Consolidated Revenue of NT$1.50 Billion in November

保瑞公告 11 月自結合併營收新台幣 15 億 0 仟萬元

Taipei, Taiwan, December 9, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for November 2025 reached NT$1.50 billion, a decrease of 10.8% compared to same period last year. Year-to-date, the Company delivered a 4.9% growth over last year.

台北，台灣，2025 年 12 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 11 月自結合併營收為新台幣 15 億 0 仟萬元，較去年同期衰退 10.8%，累計營收較去年增長 4.9%。

The month-over-month decline was primarily driven by fewer working days due to Thanksgiving holidays, as well as the anticipated entry of a new DLS competitor. Although the competitor has not yet launched, channel partners have slowed orders in anticipation of potential stocking activities. The Company will continue to monitor closely competitive landscape to form responsive tactics to support market share.

和 10 月相較，因感恩節影響北美工作天數，以及於 11 月上旬取得 DLS 學名藥藥證的新進競爭者影響下游通路備貨策略，該競爭者尚未開賣，然下游觀望氣氛濃厚。公司仍持續緊密觀察競爭者動態，以即時因應保護市佔率。

Yesterday, Subsidiary of Changchun High Tech Industry (Group) Co., Ltd. “GenSci Group”, who has partnered with our subsidiary, TWi Pharmaceuticals, to introduce Megestrol Acetate Oral Suspension into the China market, announced that the product has now been included in China’s National Reimbursement Drug List (NRDL), and GenSci is actively discussing commercial-scale CDMO manufacturing services with Bora Pharmaceuticals.

昨日，長春高新技術產業集團股份有限公司控股子公司長春金賽藥業有限責任公司（下稱金賽）與本公司子公司保盛合作，引進美適亞（醋酸甲地孕酮口服混懸液），已新納入中國醫保目錄，並積極洽談由保瑞進行 CDMO 商業量產服務。

Megestrol Acetate Oral Suspension is an exclusively listed product in China developed by TWi. In 2024, GenSci obtained exclusive distribution rights for multiple markets including China, Hong Kong, Macau, and Singapore. The currently approved indications are:

- treatment of anorexia in patients with acquired immunodeficiency syndrome (AIDS), and
- significant weight loss caused by cachexia in AIDS and cancer patients.

Powered by nano suspension technology, Megestrol Acetate Oral Suspension addresses the key clinical challenge that existing formulations require intake with a high-fat, high-calorie meal, an impossible requirement for cachectic patients who already suffer from severe anorexia. This product fills an unmet medical need for cachexia management and has thus been directly recommended by both the *2025 CSCO Guidelines for the*

Diagnosis and Treatment of Cancer-related Anorexia–Cachexia Syndrome and the *China Expert Consensus on Cancer-induced Anorexia*.

美適亞（醋酸甲地孕酮口服混懸液）在中國市場為獨家品種，由保盛開發，金賽於 2024 年獲得該產品在中國大陸、香港、澳門地區及新加坡獨家經銷和產品上市許可持有人授權，目前已獲批的適應症為「用於治療獲得性免疫缺陷綜合征患者的厭食症，及獲得性免疫缺陷綜合征患者及癌症患者惡病質引起的體重明顯減輕」。美適亞採用奈米技術創新改良，解決了本已厭食的惡病質患者服用非奈米製劑需伴隨高脂高熱餐的臨床問題，填補惡病質患者未竟的醫療需求，獲得《中國臨床腫瘤學會腫瘤厭食-惡病質綜合症診療指南 2025》和《癌因性厭食診療中國專家共識》直接推薦。

Looking ahead to 2026, the Company expects deeper integration between its pharma sales business and CDMO operations under its dual-engine strategy. This alignment will enable Bora to fully leverage the management and synergy advantages across the entire lifecycle, from in-house development and licensing, to manufacturing and commercial-scale production. By strengthening predictability, scalability, and cross-regional supply-chain integration, the Company aims to further reinforce its global competitiveness.

展望 2026 年，公司期待在雙引擎策略下，全球銷售與 CDMO 業務能有更緊密的串接，充分發揮自開發、授權、製造到商業量產各循環間的管理與協作優勢，打造更具可預測性與經濟規模的成長曲線，並提升跨區域供應鏈整合能力，進一步強化公司的全球競爭力。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

https://www.bora-corp.com

https://www.boracdmo.com

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 https://www.bora-corp.com

CDMO 網站 https://www.boracdmo.com

Investor/Media enquiries　新聞聯繫人：

Nadiya Chen, Investor Relations　投資人關係　陳荻雅

+886 2 790-1555 Ext. 9108

Email：Nadiya.Chen@bora-corp.com